{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:18:51Z","timestamp":1792703931643,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clgc.2025.102484","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:31:55Z","timestamp":1765499515000},"page":"102484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC)"],"prefix":"10.1016","volume":"24","author":[{"given":"Audreylie","family":"Lemelin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3642-4035","authenticated-orcid":false,"given":"Martin","family":"Zarba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4321-6074","authenticated-orcid":false,"given":"Kosuke","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Connor","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razane El Hajj","family":"Chehade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8449-863X","authenticated-orcid":false,"given":"Frede","family":"Donskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"De Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9066-8244","authenticated-orcid":false,"given":"Ian D.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta K.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2363-8707","authenticated-orcid":false,"given":"Aaron R.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9124-354X","authenticated-orcid":false,"given":"Ben","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6903-5357","authenticated-orcid":false,"given":"Georg A.","family":"Bjarnason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindran","family":"Kanesvaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0581-7963","authenticated-orcid":false,"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Y.C.","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2025.102484_bib0001","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211034708","article-title":"New approaches to first-line treatment of advanced renal cell carcinoma","volume":"13","author":"George","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2025.102484_bib0002","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102484_bib0003","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.eururo.2023.08.010","volume":"84","author":"Plimack","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102484_bib0004","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1470-2045(23)00049-9","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2025.102484_bib0005","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2025.102484_bib0006","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(19)30513-3","article-title":"Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study","volume":"20","author":"Ornstein","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102484_bib0007","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejca.2020.05.009","article-title":"Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma","volume":"135","author":"McGregor","year":"2020","journal-title":"Eur J Cancer"},{"issue":"10397","key":"10.1016\/j.clgc.2025.102484_bib0008","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2025.102484_bib0009","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","volume":"404","author":"Choueiri","year":"2024","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.clgc.2025.102484_bib0010","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/S1470-2045(19)30510-8","article-title":"Renal cell carcinoma treatment after first-line combinations","volume":"20","author":"Porta","year":"2019","journal-title":"Lancet Oncol"},{"issue":"39","key":"10.1016\/j.clgc.2025.102484_bib0011","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.3748\/wjg.v26.i39.6027","article-title":"Real-world treatment attrition rates in advanced esophagogastric cancer","volume":"26","author":"Tsang","year":"2020","journal-title":"World J Gastroenterol"},{"issue":"34","key":"10.1016\/j.clgc.2025.102484_bib0015","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102484_bib0013","doi-asserted-by":"crossref","first-page":"8","DOI":"10.15586\/jkcvhl.2017.59","article-title":"Predictive factors for second-line therapy in metastatic renal cell carcinoma: a retrospective analysis","volume":"4","author":"Eggers","year":"2017","journal-title":"J Kidney Cancer VHL"},{"issue":"2","key":"10.1016\/j.clgc.2025.102484_bib0014","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2025.102484_bib0012","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3233\/KCA-170020","article-title":"Fourth-line therapy in metastatic renal cell carcinoma (mRCC): results from the international mRCC database consortium (IMDC)","volume":"2","author":"Stukalin","year":"2018","journal-title":"Kidney Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T12:09:53Z","timestamp":1768910993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1558767325001843"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102484","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC)","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102484","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102484"}}